The call, on record
HIMS bullish call
Quoted text as recorded“I wouldn't be surprised to see that turnaround over the next few days and weeks.”
Our interpretation
- Source published
- Aug 11, 2026
- Timeframe
- next few days and weeks
- Interpreted confidence
- low
- Specificity
- vague
Why this call is unscored
- Status
- Not scored
- Notes
- There is no numerical target that can be objectively scored.
Email me when HIMS calls resolve
When a tracked HIMS call is scored — hit, miss or partial — we’ll email you the result. No account needed.
Used only for these updates. Privacy
Evidence and source
Our summary of the thesis
Strongly BullishStructured interpretation of the video, not a verbatim quotation. Check the source for conditions, emphasis and context.
Travis views Hims & Hers as the biggest holding in his portfolio, believing the company is deliberately sacrificing short-term margins to acquire subscribers and build a long-term healthcare aggregator platform. He argues the recent stock drop is a short-term overreaction to margin compression, while the underlying growth trajectory (accelerating revenue, subscriber adds, expanding treatment categories) is strengthening.
Key arguments
- Subscribers grew over 300,000 sequentially to 2.89 million, partly boosted by the Eucalyptus acquisition
- Monthly revenue per subscriber jumped from $8 to $92 due to GLP1 weight loss products via Novo Nordisk and Eli Lilly deals
- Full-year revenue guidance raised to $3.1-3.3 billion from $2.8-3.0 billion, with 50%+ growth expected in the second half of 2026
- International expansion (Eucalyptus, Zava, Canada) is driving growth beyond the US market
- Customer acquisition economics improve over time as cumulative gross profit per customer builds each quarter, similar to software company lifetime-value models
- Long-term aggregator thesis: adding specialties like peptides and hormone health will keep expanding subscriber base toward 5-20 million
Counter-arguments acknowledged
- Gross margin fell from ~80% to 63.8% due to lower-margin branded GLP1 products
- Adjusted EBITDA margin guidance was cut from ~11% to 9%, and the high end of EBITDA guidance was reduced from $350 million to $325 million
- Legal reserves tied to an FTC issue are weighing on near-term margins
- Stock fell about 7% after hours and remained down roughly 2.8% pre-market on the margin disappointment
Hedges and caveats (from the video)
- Short-term market reaction negative despite long-term bullish thesis
- Margin compression expected due to customer acquisition cost investments
- Growth-versus-profitability trade-off creates investor uncertainty
- Presenter acknowledges tension between growth and near-term profitability
- Stock down 7% after earnings despite positive long-term outlook
About this record
Not yet reviewed by a moderatorAI-extracted record. A quote, summary and outcome each need their own context. Moderator review does not certify investment performance.
- Source published
- Aug 11, 2026, 2:49 PM UTC
- First recorded by TubeRank
- Aug 11, 2026, 3:18 PM UTC
- Record last updated
- Oct 6, 2026, 6:32 AM UTC
- Moderator review recorded
- Not recorded
- Transcript provenance
- YouTube captions (manual or automatic)
- Recorded analysis processor/source label
- claude-sonnet-5
- This can identify a workflow rather than an exact AI model version.
- Extraction pipeline version
- v1.0.0
- Outcome methodology version
- 2026-10-06.5
- Outcome reason code
- missing_target
Recent record changes 4 shown
Oct 6, 2026, 6:32 AM UTC
corrected
- Outcome methodology version
Before2026-10-06.4
After2026-10-06.5
Oct 6, 2026, 5:14 AM UTC
corrected
- Outcome methodology version
Before2026-10-06.2
After2026-10-06.4
Oct 6, 2026, 4:00 AM UTC
corrected
- Outcome methodology version
Before2026-10-06.1
After2026-10-06.2
Oct 6, 2026, 3:27 AM UTC
missing target
- Outcome methodology version
BeforeNot recorded
After2026-10-06.1
- Recorded outcome date
BeforeNot recorded
After2026-10-06
- Outcome explanation
BeforeNot recorded
AfterThere is no numerical target that can be objectively scored.
- Outcome reason
BeforeNot recorded
AfterMissing target
Showing up to 20 recent changes. The complete feed has 5 recorded events for this call, including its initial entry. Read the full paginated history (JSON); follow nextCursor while hasMore is true.
Stored outcome evidence
- Stored reference price
- Not recorded
- Not recorded · provider not recorded
- Target as extracted
- Not recorded
- Stated deadline as extracted
- None recorded
- Recorded outcome date
- Oct 6, 2026
- Outcome price observation
- Not recorded
- Not recorded · provider not recorded
Stored explanation
There is no numerical target that can be objectively scored.
Missing timestamps, providers and versions are historical gaps. Stored observations can include daily closes; they do not show every intraday touch or prove an executable trade. Read the methodology.
Why we interpreted the confidence this way
Soft hedge ('wouldn't be surprised') without a specific price target, indicating mild bullish conviction on a short-term stock price recovery.